Project Grant R03AI185293
- This federal Project Grant award of $151,643 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research by Dr. Ornelas Sanchez at the University of Colorado-Denver to investigate the use of proteolysis targeting chimeras (PROTACs) to regulate hypoxia-inducible factors (HIFs) and their potential therapeutic applications for inflammatory bowel disease (IBD)....
- This federal Project Grant award of $524,837 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) is supporting research to investigate the role of enteric glial mechanotransduction and the impact of mechanical stress on postoperative ileus (POI) and postoperative gastrointestinal dysfunction (POGD). The research aims to better understand the pathogenic mechanisms of POI in...
- This federal Project Grant award of $358,039 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is supporting research by Nous Biosciences Inc. to evaluate a combination therapy of dolcanatide (a guanylate cyclase-C agonist) and atiprimod (a JAK-STAT inhibitor) for the treatment of murine colitis. The research aims to advance understanding of the pathogenesis of...
- This $2,842,245 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to elucidate the role of intestinal epithelial cell (IEC) injury pathways in governing anti-TNF therapy effectiveness for ulcerative colitis. The project aims to identify predictive biomarkers in formalin-fixed, paraffin-embedded (FFPE) patient biopsies that...
- This federal Project Grant award of $161,695 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research on the role of purinergic signaling in intestinal inflammation and wound healing. The principal objective is to elucidate how the purinergic receptor P2Y1 expressed in intestinal epithelial cells influences the inflammatory response and repair processes during colitis. The research...
- This $202,728 federal Project Grant awarded by the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program funds a collaborative research project to develop a theragnostic (therapeutic and diagnostic) system for inflammatory bowel diseases (IBD). The project aims to integrate data science, synthetic biology, and additive manufacturing to model the complex interplay of host, microbial, and environmental factors in IBD, and develop an engineered...
- This National Science Foundation (NSF) Project Grant, awarded under the Computer and Information Science and Engineering (CISE) program (CFDA 47.070), provides $168,690 to the Florida Institute of Technology Inc. (Florida TECH) to develop a theragnostic (therapeutic + diagnostic) system for inflammatory bowel diseases (IBD). The project aims to model the complex interplay of host, microbial, and environmental factors that trigger IBD using data science, and then leverage synthetic biology and...
- This $172,232 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to understand the causes of inflammatory bowel disease (IBD) therapy failure. The principal investigator, Dr. Simon M. Gray, a gastroenterologist at the University of North Carolina at Chapel Hill, will leverage a pre-clinical mouse model to study the immunologic and...
- The University of Chicago was awarded a $184,572 Project Grant by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to conduct research on characterizing the transmural nature of ulcerative colitis and its associated disease-related outcomes using intestinal ultrasound. The project aims to identify new therapeutic targets and endpoints in clinical trials by determining the predictors of transmural structural alterations to the bowel wall, the disease-related...
- This Project Grant award of $1,024,862.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The purpose of the award is to support the development of IMYX-3, a soluble small molecule RAB27A inhibitor, for the treatment of ulcerative colitis (UC). UC is a chronic inflammatory bowel disease affecting the colon, and...
OPTOGENETIC ACTIVATION OF ENTERIC CHOLINERGIC NEURONS TO TREAT COLITIS - PROJECT SUMMARY THE OVERARCHING OBJECTIVE OF THIS PROPOSAL IS TO ESTABLISH A NEW AND INNOVATIVE STRATEGY FOR INFLAMMATORY BOWEL DISEASE (IBD) TREATMENT THAT LEVERAGES THE IMPORTANT ROLE OF CHOLINERGIC INNERVATION IN MEDIATING INTESTINAL INFLAMMATION. CURRENT TREATMENTS OF IBD HAVE LIMITED EFFICACY AND FAIL TO PROMOTE SUSTAINED DISEASE REMISSION, NECESSITATING SURGICAL INTERVENTION IN THE MAJORITY OF PATIENTS. THE DEVELOPMENT OF AN EFFECTIVE, DURABLE, AND WELL-TOLERATED THERAPY IS A MAJOR UNMET NEED. DEVELOPING A NEUROIMMUNE THERAPY FOR IBD WILL ADD A VALUABLE AND COMPLEMENTARY NEW APPROACH TO TREATING THIS DISEASE AND HOPEFULLY REDUCING ITS LONG- TERM CONSEQUENCES. IT HAS BEEN SHOWN THAT INTESTINAL INFLAMMATION CAN LEAD TO ENTERIC NEURONAL INJURY AND SUBSEQUENT INTESTINAL DYSFUNCTION, INCLUDING DISORDERS OF GUT MOTILITY. DAMAGE TO THE ENTERIC NERVOUS SYSTEM (ENS) MAY ALSO CONTRIBUTE TO THE DEVELOPMENT AND SEVERITY OF INTESTINAL INFLAMMATION. THEREFORE, THE ENS EMERGES AS A CRITICAL PARTICIPANT IN IMMUNOMODULATION WITHIN THE GUT. PREVIOUS STUDIES HAVE DEMONSTRATED THAT CHOLINERGIC NEURONS DIRECTLY INTERACT WITH MUSCULARIS MACROPHAGES, AND THEIR NUMBERS ARE REDUCED IN INFLAMMATION. OUR PRELIMINARY DATA SHOW FOR THE FIRST TIME THAT SELECTIVE OPTOGENETIC STIMULATION OF CHOLINERGIC NEURONS ATTENUATES COLITIS, WHILE ABLATION OF ENTERIC CHOLINERGIC NEURONS WORSENS INFLAMMATION IN DSS- INDUCED ACUTE COLITIS. WE HYPOTHESIZE THAT ENTERIC CHOLINERGIC SIGNALLING CAN BE HARNESSED AS A NOVEL THERAPEUTIC STRATEGY FOR THE TREATMENT OF IBD. IN THE PROPOSED STUDY, WE WILL FIRST DETERMINE THE MECHANISM BY WHICH CHOLINERGIC SIGNALING ATTENUATES INFLAMMATION BY INVESTIGATING THE IMPACT OF CHOLINERGIC NEURONAL ACTIVATION ON MUSCULARIS MACROPHAGE POLARIZATION AND CYTOKINE PRODUCTION. SECOND, WE WILL USE OPTOGENETICS TO SELECTIVELY STIMULATE ENTERIC CHOLINERGIC NEURONS IN WINNIE MICE, A WELL-ESTABLISHED MODEL OF CHRONIC COLITIS THAT CLOSELY RESEMBLES HUMAN IBD TO DETERMINE THE EFFECT OF CHOLINERGIC SIGNALING ON DISEASE ONSET AND THE SEVERITY OF INFLAMMATION. AS PARAMETERS OF ANTI-INFLAMMATORY ACTIVITY, WE WILL INVESTIGATE CHANGES IN MORPHOLOGY AND INFLAMMATORY INDICES, AS WELL AS CHANGES IN SMOOTH MUSCLE CONTRACTILITY AND MOTILITY AS MEASURED BY ORGAN BATH EXPERIMENTS AND ELECTROMYOGRAPHY. THESE STUDIES WILL PROVIDE IMPORTANT INSIGHTS INTO THE MECHANISMS BY WHICH CHOLINERGIC NEURONS CAN IMPROVE COLITIS AND OFFER A POTENTIAL NOVEL TREATMENT STRATEGY FOR IBD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $80.1k | 4/25/25 | ||
| Not listed | $8.1k | 9/11/24 | ||
| Not listed | $8.1k | 9/11/24 | ||
| Not listed | $73.0k | 6/21/24 | ||
| Not listed | $73.0k | 6/21/24 |